

human Adenosine A1 Receptor

Product Number:	ES-010-M400UA 2399756	
Lot Number:		
		\checkmark
Material Provided Membranes:		1 x 400 units / 400 μL frozen aliquot
Product Information Cellular Background:		CHO-K1
GenBank Accession Number:		NM_000674
Unit Size:		10 µg protein / unit
Storage Buffer:		50 mM Tris-HCL (pH 7.4), 0.5mM EDTA, 10mM MgCl ₂ , 10% sucrose.
Storage Con	ditions:	Store at -80°C. Freeze-thaw is not recommended as it can affect product performance and homogeneity. In order to minimize negative impact of freeze-thawing, flash freeze in liquid nitrogen for 30 seconds prior to transferring to -80°C.
Stability:		This product is stable for at least 3 years from reception if used and stored under recommended conditions.

Quality Control


Bmax and Kd are determined using radioactive saturation binding assays (Figure 1). Protein concentration is determined using the BCA method ⁽¹⁾. Ratio-to-Reference (RTR) is determined by dividing the maximal signal of the current lot (Bmax in fmoles) by the maximal signal of a pre-defined reference tested in parallel. RTR is an indicator of lot-to-lot consistency. *We certify that these results meet our quality release criteria.

Ratio-to-Reference (RTR):	0.98			
Expression Level (B _{MAX}):	3.3 pmol/mg membrane protein.			
$K_{\mbox{\tiny D}}$ for [^3H]-Cyclopentyl-1,3-dipropylxanthine:	1.5 nM			
Protein Concentration:	10 µg/µL			
(1) Smith, P.K., et al. (1985). Anal. Biochem. 150, 76-85.				



Recommended Assay Conditions	
Assay Buffer:	25 mM Hepes pH 7.4, 5 mM MgCl ₂ , 1 mM CaCl ₂ , 100 mM NaCl
Wash Buffer:	25 mM Hepes pH 7.4, 5 mM MgCl ₂ , 1 mM CaCl ₂ , 100 mM NaCl
Binding Protocol:	Binding assays are performed in 550 μL total volume according to the following conditions:
1 - Membrane dilution:	0.05 mL of membranes + 24.95 mL assay buffer (1:500 dilution)
2 - Incubation:	25 μL of incubation buffer or 8-Cyclopentyl-1,3-dipropylxanthine (Sigma C101) 10 μM final for non-specific binding (Saturation binding assay)
	For competition binding assay: 25 µL of reference compounds at decreasing concentrations (see figure 2)
	25 μL of radioligand at the appropriate concentration (see graph below) 500 μL of diluted membranes
3 - Incubation time:	60 minutes at 27 °C
4 - Filtration:	aspirate and wash 9 x 500 μL with ice cold wash buffer over GF/C filter (presoaked in 0.5 $\%$ PEI).

Lot Specific Data



[3H]-Cyclopentyl-1,3-dipropylxanthine (nM)

Figure 1: Saturation binding assay curve (filtration) 96-well saturation binding assay curve (10 µg membranes/well, TopCount®) using [³H]-Cyclopentyl-1,3dipropylxanthine (Revvity NET974 Lot No.: 2383345)



Typical Product Data




Figure 2: Competition binding assay curve (filtration) 96-well competition binding assay curve (10 µg membranes/well, TopCount®). Recommended radioligand concentration = 1.7 nM.

*Even though two sites can be observed occasionally with some ligands, the data presented is derived from single site fitting.

Reference Compounds	Ki
	(nM)
8-Cyclopentyl-1,3-dipropylxanthine	17
GR 79236	165
1,3-Dipropyl-8-phenylxanthine	576
2-Chloro-№-Cyclopentyladenosine	38

This product is not for resale or distribution except by authorized distributors. The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.



Revvity 940 Winter Street Waltham, MA 02451 USA

(800) 762-4000 www.revvity.com For a complete listing of our global offices, visit <u>www.revvity.com</u> Copyright ©2023, Revvity, Inc. All rights reserved.